Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.

Q: What does this research mean for the field?

Approximately 1 in 25 patients treated with enzalutamide plus leuprolide for 9 months achieved sustained PSA <0.2 ng/mL and testosterone recovery 3 years post-therapy, indicating long-term remissions are possible with hormonal therapy only. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate the proportion of prostate cancer patients achieving sustained PSA <0.2 ng/mL after hormonal therapy suspension despite testosterone recovery.

Neal D. Shore; Vincenzo De Giorgi; Martin Gleave; Matko Kalac; Yiyun Tang; Ruslan Croitoru; Matt Rosales; Manish Patel; Antonio Finelli; Zvi Schiffman; Anna Lantz; Stephen J. Freedland

doi:10.1200/jco.2026.44.7_suppl.189

March 1, 2026Journal of Clinical Oncology

Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the proportion of prostate cancer patients achieving sustained PSA <0.2 ng/mL after hormonal therapy suspension despite testosterone recovery.
Post hoc analysis of the EMBARK trial data
Randomized patients to receive enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy
Assessed rates of PSA <0.2 ng/mL at 12, 24, and 36 months after treatment suspension.
9.3% of patients in the enza combo group maintained PSA <0.2 ng/mL after 36 months
1.4% and 1.1% of patients in the LA and enza mono groups maintained PSA <0.2 ng/mL, respectively
Indicates a higher long-term remission rate in patients treated with enza combo compared to other therapies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Post hoc analysis evaluates sustained PSA <0.2 ng/mL in prostate cancer patients after hormonal therapy suspension, indicating potential long-term benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shore et al. (2026) studied this question.

synapsesocial.com/papers/69a7cdaed48f933b5eeda3f5 https://doi.org/10.1200/jco.2026.44.7_suppl.189

View at Publisher

Ask AI

Bookmark

Share

Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading